pleckstrin homology, MyTH4 and FERM domain containing H1Genealiases: []
Q-omics provides the consensus-scored PLEKHH1 profile across patient tissues and cancer cell-line models. PLEKHH1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PLEKHH1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, PLEKHH1 RNA expression shows 20,536 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, THCA, and UVM as cancer lineages where PLEKHH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHH1 survival associations across molecular data types. PLEKHH1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHH1 RNA expression–survival associations across cancer types. High PLEKHH1 expression shows unfavorable associations in LUAD, LIHC and UVM, but favorable associations in UCEC, BRCA and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PLEKHH1 RNA expression.
This table summarizes PLEKHH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PLEKHH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHH1 shows lower tumor expression in THCA and KIRC and higher tumor expression in LIHC, UCEC, CHOL and STAD. The THCA box plot shows higher PLEKHH1 RNA expression in normal versus tumor tissue (log2 FC = −1.978, t-test p < 0.001).
This table shows molecular features associated with PLEKHH1 in patient tissues and cancer cell lines. In patient samples, PLEKHH1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
